Abstract Number: 0210 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
Background/Purpose: Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active RA. In the TARGET study…Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…Abstract Number: 0744 • ACR Convergence 2020
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning
Background/Purpose: Rheumatoid arthritis (RA) can lead to changes in body composition, including muscle loss and excess adiposity, which are in turn associated with physical disability.…Abstract Number: 0850 • ACR Convergence 2020
What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials
Background/Purpose: BICLA is a validated composite global measure of SLE disease activity that incorporates BILAG, an instrument that distinguishes between partial and complete improvement. BICLA…Abstract Number: 1129 • ACR Convergence 2020
Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
Background/Purpose: Relapsing polychondritis (RP) is a rare chronic disabling inflammatory condition primarily affecting cartilage tissue. Self-reported patient outcome measures, which have not been evaluated in…Abstract Number: 1277 • ACR Convergence 2020
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at an increased risk of infection owing to immunosuppressive therapy along with coexistent immune dysregulation. It is…Abstract Number: 1540 • ACR Convergence 2020
Association Between Disease Activity and Left Ventricular Systolic Function in Patients with Rheumatoid Arthritis: A Case-Control Study
Background/Purpose: Patients with Rheumatoid Arthritis(RA) have a higher prevalence of Cardiovascular Disease (CVD), which is the most common cause of death in this group. Disease…Abstract Number: 1731 • ACR Convergence 2020
Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan
Background/Purpose: Disease activity in rheumatoid arthritis (RA) patients is usually measured by an index like DAS28,1 a composite measure consisting of 28 swollen and/or tender…Abstract Number: 1829 • ACR Convergence 2020
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Background/Purpose: In the randomized, double-blind, phase 2b MUSE trial, anifrolumab reduced disease activity vs placebo across multiple endpoints in patients with moderately to severely active…Abstract Number: 0247 • ACR Convergence 2020
Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Background/Purpose: This study aimed to examine the frequency and risk factors of complications during pregnancy in women with systemic lupus erythematosus (SLE).Methods: The medical records…Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…Abstract Number: 0746 • ACR Convergence 2020
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Background/Purpose: Small RNAs (sRNAs), including microRNAs (miRNAs) and yRNA-derived sRNAs (yDRs), are important gene regulators and markers of disease. HDL, while known for its anti-atherogenic…Abstract Number: 0871 • ACR Convergence 2020
Hydroxychloroquine Dose Reduction and SLE Flares
Background/Purpose: 2016 ophthalmology guidelines recommend using hydroxychloroquine (HCQ) dosages < 5mg/kg/day, which is lower than the traditional 400mg/day for the majority of SLE patients. However,…Abstract Number: 1141 • ACR Convergence 2020
Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM
Background/Purpose: Treat-to-target (T2T), achieving a DAS28 below 3.2 is the main management strategy for RA. The Chinese New Year is a long holiday started in…Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 112
- Next Page »